Central Vision Articles & Analysis
6 news found
About nAMD and DME Neovascular (wet) age-related macular degeneration (nAMD) is an eye disease that progresses rapidly and if left untreated can lead to vision loss in as little as three months. nAMD is one of the leading causes of irreversible blindness and vision impairment around the world. nAMD may affect people as they age. It occurs when abnormal blood ...
ByBayer AG
Aflibercept 8 mg has been developed with the aim to increase intervals between injections without compromising vision gains. “Extended treatment intervals meet an important patient need by significantly reducing the disease burden for patients with exudative retinal diseases. ...
ByBayer AG
Similar reductions in mean change of central retinal thickness (CRT) were achieved in nAMD and DME patients receiving aflibercept 8 mg with 12- and 16-week dosing versus Eylea (aflibercept 2 mg) with 8-week dosing at week 48. ...
ByBayer AG
Similar reductions in mean change of central retinal thickness (CRT) from baseline were achieved in patients receiving aflibercept 8 mg 12- and 16-week dosing versus Eylea with 8-week dosing at week 48. ...
ByBayer AG
About Dry Age-Related Macular Degeneration (AMD) and Geographic Atrophy (GA) Dry AMD is a leading cause of permanent vision loss in people over the age of 50 and is a devastating diagnosis.[1] There are currently no approved treatments for dry AMD, which is the most common form, impacting approximately 85-90% of people with AMD.[2] As dry AMD advances, it leads to GA, an ...
To do this they will need to learn to be architects with a view of the big picture and a vision for where this process needs to go in the short, medium and long-term. This means having a realistic vision of where progress can be made between now and Durban, capitalizing on areas where a great deal of agreement already exists, and parking remaining issues for ...